(Q48497164)

12 February 2018

title

High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. (English)

1 reference

12 February 2018

1 reference

S M Chang

1

1 reference

12 February 2018

F G Barker

2

1 reference

12 February 2018

S L Huhn

3

1 reference

12 February 2018

M K Nicholas

4

1 reference

12 February 2018

M Page

5

1 reference

12 February 2018

J Rabbitt

6

1 reference

12 February 2018

M D Prados

7

1 reference

12 February 2018

publication date

1 April 1998

1 reference

12 February 2018

Journal of Neuro-Oncology

published in

1 reference

12 February 2018

volume

37

1 reference

12 February 2018

issue

2

1 reference

12 February 2018

page(s)

169-176

1 reference

12 February 2018

https://scigraph.springernature.com/pub.10.1023/a:1005826323652

exact match

0 references

cites work

Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

1 reference

12 December 2020

Decreased phenytoin levels in patients receiving chemotherapy

1 reference

12 December 2020

Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C

1 reference

12 December 2020

High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator

1 reference

12 December 2020

A phase I trial of high-dose oral tamoxifen and CHOPE

1 reference

12 December 2020

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

1 reference

12 December 2020

A Phase II study of high dose tamoxifen in progressive, metastatic renal cell

1 reference

12 December 2020

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

1 reference

12 December 2020

Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen

1 reference

12 December 2020

The Efficacy of Tamoxifen as an Antiproliferative Agent in vitro for Benign and Malignant Pediatric Glial Tumors

1 reference

12 December 2020

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

12 December 2020

Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study

1 reference

12 December 2020

MDR1 gene expression in brain of patients with medically intractable epilepsy

1 reference

12 December 2020

Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro

1 reference

12 December 2020

Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.

1 reference

12 December 2020

The effects of interferon on glial cells.

1 reference

12 December 2020

Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen

1 reference

12 December 2020

Effect of human leukocyte interferon on malignant brain tumors.

1 reference

12 December 2020

Effect of Recombinant Fibroblast Interferon and Recombinant Immune Interferon on Growth and the Antigenic Phenotype of Multidrug-Resistant Human Glioblastoma Multiforme Cells

1 reference

12 December 2020

Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.

1 reference

12 December 2020

Treatment of lymphangioleiomyomatosis by ovariectomy, interferon alpha 2b and tamoxifen--a case report

1 reference

12 December 2020

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours

1 reference

12 December 2020

A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro.

1 reference

12 December 2020

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

1 reference

12 December 2020

Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways.

1 reference

12 December 2020

High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression

1 reference

12 December 2020

The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme

1 reference

12 December 2020

Intratumor application of human leukocyte interferon-alpha in patients with malignant brain tumors.

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas

1 reference

12 December 2020

The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients

1 reference

12 December 2020

Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review

1 reference

12 December 2020

High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs

1 reference

12 December 2020

Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity.

1 reference

12 December 2020

Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines

1 reference

12 December 2020

The interferons. Mechanisms of action and clinical applications

1 reference

12 December 2020

Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer

1 reference

12 December 2020

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

1 reference

12 December 2020

Central nervous system toxicity of interferon.

1 reference

12 December 2020

Intratumoural and intraventricular human lymphoblastoid alpha interferon (HLBI) for treatment of glioblastoma multiforme.

1 reference

12 December 2020

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

12 December 2020

Phase II study of paclitaxel in patients with recurrent malignant glioma.

1 reference

12 December 2020

High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines

1 reference

12 December 2020

Inhibition of protein kinase C by tamoxifen.

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients

1 reference

12 December 2020

Interferons in the treatment of human cancer

1 reference

12 December 2020

Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1005826323652

1 reference

12 February 2018

Dimensions Publication ID

1011775122

0 references

1 reference

12 February 2018